FDA Questions Efficacy of Abbott’s Humira in Treating Ulcerative Colitis

Drug Industry Daily
A A
FDA staff is questioning the efficacy of Abbott Laboratories’ blockbuster Humira in treating ulcerative colitis (UC) and suggesting additional trials may be necessary.

To View This Article:

Login

Subscribe To Drug Industry Daily